CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Genetics, Epidemiology, and Prevention

Purpose: To address the most dynamic and current issues concerning human genetics, risk factors, pharmacoeconomics, and prevention regarding age-related macular degeneration. Methods: An online review of the database Pubmed and Ovid was performed, searching for the key words: age-related macular degeneration, AMD, pharmacoeconomics, risk factors, VEGF, prevention, genetics and their compound phrases. The search was limited to articles published since 1985 to date. All returned articles were carefully screened and their references were manually reviewed for additional relevant data. The webpage www.clinicaltrials.gov was also accessed in search of relevant research trials. Results: A total of 366 articles were reviewed, including 64 additional articles extracted from the references and 25 webpages and online databases from different institutions. At the end, only 244 references were included in this review. Conclusion: Age-related macular degeneration is a complex multifactorial disease that has an uneven manifestation around the world but with one common denominator, it is increasing and spreading. The economic burden that this disease poses in developed nations will increase in the coming years. Effective preventive therapies need to be developed in the near future.

[1]  T. Wong,et al.  Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. , 2008, Archives of ophthalmology.

[2]  J. Saaddine,et al.  Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. , 2009, Archives of ophthalmology.

[3]  Ku Chee Seng,et al.  The success of the genome-wide association approach: a brief story of a long struggle , 2008, European Journal of Human Genetics.

[4]  P. Mitchell,et al.  Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study. , 2008, Ophthalmology.

[5]  P. Mitchell,et al.  Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study. , 2009, Archives of ophthalmology.

[6]  M. Smith-Wheelock,et al.  Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. , 2004, Investigative ophthalmology & visual science.

[7]  S. Mousa,et al.  Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration , 2010, BioDrugs.

[8]  J. Rivera,et al.  Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity , 2010, Clinical ophthalmology.

[9]  S. Fisher,et al.  Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA , 2008, Nature Genetics.

[10]  Anand Swaroop,et al.  Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. , 2009, Annual review of genomics and human genetics.

[11]  C. Cross,et al.  Cigarette Smoke Oxidation of Human Plasma Constituents a , 1993, Annals of the New York Academy of Sciences.

[12]  A. Issa,et al.  The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence , 2010, British Journal of Ophthalmology.

[13]  Ronald Klein,et al.  Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. , 2009, Ophthalmology.

[14]  Julie A Simpson,et al.  Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis. , 2008, American journal of ophthalmology.

[15]  H. Loi,et al.  Myositis Ossificans , 2011, The western journal of emergency medicine.

[16]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Usha Chakravarthy,et al.  Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). , 2006, Archives of ophthalmology.

[18]  R. Wormald,et al.  Is the incidence of registrable age-related macular degeneration increasing? , 1996, The British journal of ophthalmology.

[19]  M. Parodi,et al.  MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration , 2005, Genetics in Medicine.

[20]  A. Nicolucci,et al.  Four‐year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD‐Annals initiative , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[21]  P. Bernstein,et al.  HTRA1 Variant Confers Similar Risks to Geographic Atrophy and Neovascular Age-related Macular Degeneration , 2007, Cell cycle.

[22]  Simon J. Clark,et al.  Complement factor H and age-related macular degeneration: the role of glycosaminoglycan recognition in disease pathology. , 2010, Biochemical Society transactions.

[23]  E. Friedman.  Update of the vascular model of AMD , 2004, British Journal of Ophthalmology.

[24]  C. Pang,et al.  The Apolipoprotein E ε4 Allele Is Unlikely to Be a Major Risk Factor of Age-Related Macular Degeneration in Chinese , 2000, Ophthalmologica.

[25]  P. Mitchell,et al.  Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. , 2002, Archives of ophthalmology.

[26]  P. Mitchell,et al.  Prevalence and causes of visual impairment and blindness in an urban Indian population: the Singapore Indian Eye Study. , 2011, Ophthalmology.

[27]  Victoria A. Higman,et al.  His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form* , 2006, Journal of Biological Chemistry.

[28]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[29]  J. Olson,et al.  VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration , 2009, Expert opinion on investigational drugs.

[30]  B S Hawkins,et al.  Epidemiology of age-related macular degeneration. , 1999, Molecular vision.

[31]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[32]  J. Hoh,et al.  HTRA1 variants in exudative age-related macular degeneration and interactions with smoking and CFH. , 2008, Investigative ophthalmology & visual science.

[33]  A F Smith.  The growing importance of pharmacoeconomics: the case of age-related macular degeneration , 2010, British Journal of Ophthalmology.

[34]  Emily Y Chew,et al.  Summary results and recommendations from the age-related eye disease study. , 2009, Archives of ophthalmology.

[35]  C. Serhan.  Novel omega -- 3-derived local mediators in anti-inflammation and resolution. , 2005, Pharmacology & therapeutics.

[36]  H. Taylor,et al.  Age-specific causes of bilateral visual impairment. , 2000, Archives of ophthalmology.

[37]  B. Ivandic,et al.  Low-level laser therapy improves vision in patients with age-related macular degeneration. , 2008, Photomedicine and laser surgery.

[38]  R. Kim,et al.  Prevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study. , 2004, Archives of ophthalmology.

[39]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[40]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[41]  G. Tikellis,et al.  Apolipoprotein (APOE) gene is associated with progression of age‐related macular degeneration (AMD) , 2006, Human mutation.

[42]  Tianjing Li,et al.  Statins for age-related macular degeneration. , 2009, The Cochrane database of systematic reviews.

[43]  C. Delcourt,et al.  Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liées à l'Age (POLA) study. , 2001, Archives of ophthalmology.

[44]  E. Dratz,et al.  A reinvestigation of the fatty acid content of bovine, rat and frog retinal rod outer segments. , 1979, Experimental eye research.

[45]  I. Wong,et al.  Prevention of age-related macular degeneration , 2010, International Ophthalmology.

[46]  E. Souied,et al.  [Epidemiology of age related macular degeneration]. , 2009, Journal Francais d'Ophtalmologie.

[47]  Robyn H Guymer,et al.  The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.

[48]  V. Sheffield,et al.  Missense variations in the fibulin 5 gene and age-related macular degeneration. , 2004, The New England journal of medicine.

[49]  A. Hofman,et al.  Genetic association of apolipoprotein E with age-related macular degeneration. , 1998, American journal of human genetics.

[50]  G. Chodick,et al.  Statin Use and the Risk of Age Related Macular Degeneration in a Large Health Organization in Israel , 2011, Ophthalmic epidemiology.

[51]  R. Yamada,et al.  Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age‐related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population , 2008, Clinical & experimental ophthalmology.

[52]  N. Bazan.  The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology. , 1989, Progress in clinical and biological research.

[53]  J. Haines,et al.  Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. , 1997, Investigative ophthalmology & visual science.

[54]  Leslie Hyman,et al.  A Simplified Severity Scale for Age-Related Macular Degeneration , 2005 .

[55]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[56]  M. Tso,et al.  Antiretinal antibodies in serum of patients with age-related macular degeneration. , 1991, Ophthalmology.

[57]  S. D. de Córdoba,et al.  Translational Mini‐Review Series on Complement Factor H: Genetics and disease associations of human complement factor H , 2007, Clinical and experimental immunology.

[58]  R. Guymer,et al.  Analysis of the EFEMP1 gene in individuals and families with early onset drusen , 2005, Eye.

[59]  Leopold Schmetterer,et al.  Nutritional supplements in age‐related macular degeneration , 2015, Acta ophthalmologica.

[60]  Gonçalo R. Abecasis,et al.  A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration , 2007, Proceedings of the National Academy of Sciences.

[61]  B S Hawkins,et al.  Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. , 1997, Ophthalmology.

[62]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[63]  J. Haines,et al.  Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. , 2007, Human molecular genetics.

[64]  B. Ames,et al.  Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes. , 2000, The American journal of clinical nutrition.

[65]  J. Ott,et al.  Lack of an association of apolipoprotein E gene polymorphisms with familial age-related macular degeneration. , 2003, Archives of ophthalmology.

[66]  Johanna M Seddon,et al.  Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. , 2003, Ophthalmology.

[67]  T. Das,et al.  Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. , 2008, Investigative ophthalmology & visual science.

[68]  V. Zannis.  Genetic polymorphism in human apolipoprotein E. , 1986, Methods in enzymology.

[69]  G. Abecasis,et al.  Meta-analysis of genome scans of age-related macular degeneration. , 2005, Human molecular genetics.

[70]  A. Hofman,et al.  A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. , 2006, Journal of the American College of Cardiology.

[71]  D. Clayton,et al.  Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation , 2005, British Journal of Ophthalmology.

[72]  Johanna M Seddon,et al.  Variation in complement factor 3 is associated with risk of age-related macular degeneration , 2007, Nature Genetics.

[73]  K. Lewandrowski,et al.  Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? , 2003, Archives of pathology & laboratory medicine.

[74]  J. Attia,et al.  Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. , 2006, American journal of epidemiology.

[75]  R. Yamada,et al.  ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. , 2009, American journal of ophthalmology.

[76]  C. Curcio,et al.  Morphometric analysis of lipoprotein-like particle accumulation in aging human macular Bruch's membrane. , 2008, Investigative ophthalmology & visual science.

[77]  P. Mitchell,et al.  Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials , 2009, British Journal of Ophthalmology.

[78]  I. Deary,et al.  Complement C3 variant and the risk of age-related macular degeneration. , 2007, The New England journal of medicine.

[79]  Amitha Domalpally,et al.  The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). , 2012, Ophthalmology.

[80]  I. Constable,et al.  Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. , 2009, Ophthalmology.

[81]  A. Edwards,et al.  Complement Factor H Polymorphism and Age-Related Macular Degeneration , 2005, Science.

[82]  V. Zannis.  [49] Genetic polymorphism in human apolipoprotein E , 1986 .

[83]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[84]  S. Fisher,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .

[85]  D. Do.  Antiangiogenic approaches to age-related macular degeneration in the future. , 2009, Ophthalmology.

[86]  T. Das,et al.  Risk factors for age-related macular degeneration: findings from the Andhra Pradesh eye disease study in South India. , 2005, Investigative ophthalmology & visual science.

[87]  A. Salminen,et al.  NF-κB signaling as a putative target for ω-3 metabolites in the prevention of age-related macular degeneration (AMD) , 2009, Experimental Gerontology.

[88]  CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. , 2007, Human molecular genetics.

[89]  Spending on genetic tests grows , 2012, American Journal of Medical Genetics. Part A.

[90]  R. Klein,et al.  Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. , 1995, Ophthalmology.

[91]  S. Kelly,et al.  Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK , 2012, PharmacoEconomics.

[92]  M. Walport,et al.  Complement. Second of two parts. , 2001, The New England journal of medicine.

[93]  U. Kellner,et al.  FUNDUS AUTOFLUORESCENCE (488 NM) AND NEAR-INFRARED AUTOFLUORESCENCE (787 NM) VISUALIZE DIFFERENT RETINAL PIGMENT EPITHELIUM ALTERATIONS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION , 2010, Retina.

[94]  C. Hennekens,et al.  Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. , 2000, Annals of epidemiology.

[95]  Marco A Zarbin,et al.  PATHWAY-BASED THERAPIES FOR AGE-RELATED MACULAR DEGENERATION: An Integrated Survey of Emerging Treatment Alternatives , 2010, Retina.

[96]  Johanna M Seddon,et al.  Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.

[97]  S. Chakrabarti,et al.  The molecular genetic basis of age-related macular degeneration: an overview , 2009, Journal of Genetics.

[98]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[99]  G. Parmigiani,et al.  Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. , 2008, The New England journal of medicine.

[100]  T. Matise,et al.  Age-related macular degeneration--a genome scan in extended families. , 2003, American journal of human genetics.

[101]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[102]  Jie-Jin Wang,et al.  Age‐specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study , 2000, Clinical & experimental ophthalmology.

[103]  J. Raftery,et al.  Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness , 2007, British Journal of Ophthalmology.

[104]  A. Edwards.  Genetic testing for age-related macular degeneration. , 2006, Ophthalmology.

[105]  C. Galván,et al.  Serological association between Chlamydia pneumoniae infection and age-related macular degeneration. , 2002, Archives of ophthalmology.

[106]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[107]  Baitang Ning,et al.  Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[108]  R. Bhisitkul,et al.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[109]  M. Daly,et al.  Variation near complement factor I is associated with risk of advanced AMD , 2009, European Journal of Human Genetics.

[110]  R. Klein,et al.  Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. , 2006, Ophthalmology.

[111]  Na Rae Kim,et al.  Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans. , 2008, Investigative ophthalmology & visual science.

[112]  G. Braemer.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[113]  R. Klein,et al.  Sociodemographic factors and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. , 2005, American journal of ophthalmology.

[114]  V. Sheffield,et al.  An analysis of allelic variation in the ABCA4 gene. , 2001, Investigative ophthalmology & visual science.

[115]  Ronald Klein,et al.  A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. , 2005, Archives of ophthalmology.

[116]  Jennifer R. Evans,et al.  Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. , 2012, The Cochrane database of systematic reviews.

[117]  Ke Liu,et al.  Association of complement factor H polymorphisms with exudative age-related macular degeneration. , 2006, Molecular vision.

[118]  Robert F Mullins,et al.  A role for local inflammation in the formation of drusen in the aging eye. , 2002, American journal of ophthalmology.

[119]  K. Nakanishi,et al.  A2E, a byproduct of the visual cycle , 2003, Vision Research.

[120]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[121]  D. Bernanke,et al.  Development of the coronary blood supply: Changing concepts and current ideas , 2002, The Anatomical record.

[122]  K. Blennow,et al.  Association of complement factor H Y402H gene polymorphism with Alzheimer's disease , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[123]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[124]  Johanna M Seddon,et al.  The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. , 2005, Archives of ophthalmology.

[125]  M. Klein,et al.  Heredity and age-related macular degeneration. Observations in monozygotic twins. , 1994, Archives of ophthalmology.

[126]  C. Sen,et al.  Anti-angiogenic Property of Edible Berries , 2002, Free radical research.

[127]  K. Grønseth,et al.  Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. , 1996, The American journal of cardiology.

[128]  J. J. Wang,et al.  The prevalence of age-related maculopathy: the visual impairment project. , 2000, Ophthalmology.

[129]  K. Matsuo,et al.  Association between the SERPING1 Gene and Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese , 2011, PloS one.

[130]  山城 健児.  Age-Related Eye Disease Study 2 (特集 臨床において必要なサプリメントの知識) , 2012 .

[131]  A. Munnich,et al.  The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. , 1998, American journal of ophthalmology.

[132]  D. Snodderly,et al.  Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related Eye Disease Study. An ancillary study of the women's health initiative. , 2008, Ophthalmology.

[133]  G. Jarvik,et al.  Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. , 1997, Annals of epidemiology.

[134]  T. Kubota,et al.  Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability , 2011, Journal of ophthalmology.

[135]  R. Guymer,et al.  HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration? , 2005, Survey of ophthalmology.

[136]  Santa Jeremy Ono,et al.  Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. , 2009, Journal of autoimmunity.

[137]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[138]  A. Ramé.  [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[139]  M. Sporn,et al.  Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration , 2010, Vision Research.

[140]  M. Maguire,et al.  Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. , 2008, Ophthalmology.

[141]  Robert B Sim,et al.  Sequence polymorphism of human complement factor H , 2004, Immunogenetics.

[142]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[143]  C. Serhan,et al.  Resolvins and protectins in the termination program of acute inflammation. , 2007, Trends in immunology.

[144]  R. T. Smith,et al.  Comprehensive analysis of the candidate genes CCL2, CCR2, and TLR4 in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[145]  A. Hofman,et al.  Complement component C3 and risk of age-related macular degeneration. , 2008, Ophthalmology.

[146]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[147]  R. Guymer,et al.  New era for personalized medicine: the diagnosis and management of age‐related macular degeneration , 2009, Clinical & experimental ophthalmology.

[148]  R. Mullins,et al.  Macrophages in neovascular age-related macular degeneration: friends or foes? , 2009, Eye.

[149]  R. Guymer,et al.  Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. , 2006, Investigative ophthalmology & visual science.

[150]  J. Lupski,et al.  Genotype-phenotype analysis of ABCR variants in macular degeneration probands and siblings. , 2002, Investigative ophthalmology & visual science.

[151]  G. Abecasis,et al.  Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. , 2005, Human molecular genetics.

[152]  Stephen J. Ryan.  Bruch’s Membrane , 1976 .

[153]  J. McNeil,et al.  Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration. , 2005, American journal of epidemiology.

[154]  J. Vander.  Risk Factors for the Incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 19Milton RC, for the Age-Related Eye Disease Study Research Group (EMMES Corp, Rockville, Md; et al) Ophthalmology 112:533–539, 2005§ , 2006 .

[155]  P. Blomquist,et al.  Etiology of blindness in an urban community hospital setting. , 2001, Ophthalmology.

[156]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[157]  S C Jensen,et al.  Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. , 1999, Ophthalmology.

[158]  Dean P. Jones,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. , 2001, Archives of ophthalmology.

[159]  A Hofman,et al.  Genetic risk of age-related maculopathy. Population-based familial aggregation study. , 1998, Archives of ophthalmology.

[160]  G. Rubin,et al.  Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. , 2000, Archives of ophthalmology.

[161]  R. Allikmets,et al.  Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. , 2000, American journal of human genetics.

[162]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[163]  Yun Li,et al.  CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration , 2006, Nature Genetics.

[164]  Katherine M. James,et al.  Toll-like receptor polymorphisms and age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[165]  P. Charbel Issa,et al.  The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[166]  Neovascular age-related macular degeneration: decision making and optimal management , 2010, Eye.

[167]  Lars G Fritsche,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. , 2005, Human molecular genetics.

[168]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[169]  Bin Wang,et al.  HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis. , 2009, Annals of epidemiology.

[170]  G. A. Limb,et al.  Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. , 1999, Investigative ophthalmology & visual science.

[171]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[172]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[173]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[174]  G. Virgili,et al.  Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. , 2009, The Cochrane database of systematic reviews.

[175]  J. Haines,et al.  Localization of age-related macular degeneration-associated ARMS2 in cytosol, not mitochondria. , 2009, Investigative ophthalmology & visual science.

[176]  J. Hoh,et al.  Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population , 2008, Molecular vision.

[177]  C. Stanislaw,et al.  Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal, and Financial Implications , 2012, Cancer journal.

[178]  M. Margaglione,et al.  Apolipoprotein E Polymorphisms in Age-Related Macular Degeneration in an Italian Population , 2001, Ophthalmic Research.

[179]  P. Barberger‐Gateau,et al.  Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. , 2006, Investigative ophthalmology & visual science.

[180]  A. Luff,et al.  An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment , 2008, Eye.

[181]  Irina Petrache,et al.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. , 2004, The Journal of clinical investigation.

[182]  J. Haines,et al.  A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy , 2002, Ophthalmic genetics.

[183]  J. Tong,et al.  Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[184]  G. Curhan,et al.  DASH-style diet associates with reduced risk for kidney stones. , 2009, Journal of the American Society of Nephrology : JASN.

[185]  A. Swaroop,et al.  Microarray analysis of gene expression in the aging human retina. , 2002, Investigative ophthalmology & visual science.

[186]  G. Abecasis,et al.  A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants , 2007, Science.

[187]  G. Abecasis,et al.  Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. , 2007, Human molecular genetics.

[188]  R. Browne,et al.  Characterization of peroxidized lipids in Bruch's membrane. , 1999, Retina.

[189]  E. Rimm,et al.  A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. , 2007, Archives of ophthalmology.

[190]  P. Tommila,et al.  The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration , 2007, European journal of ophthalmology.

[191]  J. Haines,et al.  C3 R102G polymorphism increases risk of age-related macular degeneration. , 2008, Human molecular genetics.

[192]  ECB Monthly Bulletin , 2012 .

[193]  J. Sangiovanni,et al.  The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina , 2005, Progress in Retinal and Eye Research.

[194]  A. Munnich,et al.  The γ e4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration , 1998 .

[195]  Yvette P Conley,et al.  The genetics of age-related macular degeneration. , 2003, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[196]  M. Varano,et al.  Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. , 2008, Ophthalmology.

[197]  Ulf Eriksson,et al.  Vascular endothelial growth factors VEGF‐B and VEGF‐C , 1997, Journal of cellular physiology.

[198]  Mary T. Roth,et al.  Evidence for the Cardioprotective Effects of Omega-3 Fatty Acids , 2002, The Annals of pharmacotherapy.

[199]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[200]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[201]  M. Brantley,et al.  Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab , 2008, British Journal of Ophthalmology.

[202]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[203]  A. Hofman,et al.  Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. , 2006, JAMA.

[204]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[205]  N. Mata,et al.  Pharmacologic treatment of atrophic age-related macular degeneration , 2010, Current opinion in ophthalmology.

[206]  E. Chiquette,et al.  Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy , 1998, Journal of Thrombosis and Thrombolysis.

[207]  D. Friedman,et al.  Prevalence of age-related macular degeneration in a rural Chinese population: the Handan Eye Study. , 2011, Ophthalmology.

[208]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[209]  S. Hawken,et al.  A genetic approach to stratification of risk for age-related macular degeneration. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[210]  John D Lambris,et al.  Drusen complement components C3a and C5a promote choroidal neovascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[211]  P. Mitchell,et al.  Toll-like receptor polymorphisms and age-related macular degeneration: replication in three case-control samples. , 2009, Investigative ophthalmology & visual science.

[212]  R. Klein,et al.  Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. , 2003, Ophthalmology.

[213]  R. Klein,et al.  Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. , 2004, Ophthalmology.

[214]  Robert W. Massof,et al.  Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.

[215]  Matthew D. Davis,et al.  The Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration , 2015 .

[216]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[217]  W. MacNee,et al.  Role of oxidants/antioxidants in smoking-induced lung diseases. , 1996, Free radical biology & medicine.

[218]  W. Willett,et al.  Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. , 2008, The American journal of clinical nutrition.

[219]  B. Rosner,et al.  Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. , 2006, Archives of ophthalmology.

[220]  G. Murthy,et al.  Prevalence of early and late age-related macular degeneration in a rural population in northern India: the INDEYE feasibility study. , 2007, Investigative ophthalmology & visual science.

[221]  J M Seddon,et al.  Familial aggregation of age-related maculopathy. , 1997, American journal of ophthalmology.

[222]  G. Antes,et al.  Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review , 2010, British Journal of Ophthalmology.

[223]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[224]  J. Evans,et al.  Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. , 2006, The Cochrane database of systematic reviews.

[225]  J. Nowak,et al.  Age-related macular degeneration (AMD): pathogenesis and therapy. , 2006, Pharmacological reports : PR.

[226]  Johanna M Seddon,et al.  Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration , 2006, Nature Genetics.

[227]  Anat Loewenstein,et al.  THE SIGNIFICANCE OF EARLY DETECTION OF AGE-RELATED MACULAR DEGENERATION: Richard & Hinda Rosenthal Foundation Lecture, The Macula Society 29th Annual Meeting , 2007, Retina.

[228]  L. Fan,et al.  Toll‐like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[229]  J. Haines,et al.  Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. , 2006, American journal of human genetics.

[230]  R. Müller,et al.  External beam radiation in patients suffering from exudative age-related macular degeneration , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[231]  E. Stefánsson,et al.  Age related macular degeneration in monozygotic twins and their spouses in Iceland. , 1999, Acta ophthalmologica Scandinavica.

[232]  R. Klein,et al.  The economic burden of major adult visual disorders in the United States. , 2006, Archives of ophthalmology.

[233]  A. Hofman,et al.  Dietary intake of antioxidants and risk of age-related macular degeneration. , 2005, JAMA.

[234]  Jeffrey L. Olson,et al.  CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Today’s and Future Treatments , 2013, Retina.

[235]  Don H. Anderson,et al.  Y402H Polymorphism of Complement Factor H Affects Binding Affinity to C-Reactive Protein1 , 2007, The Journal of Immunology.

[236]  J. Hoh,et al.  HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration , 2007, Molecular vision.

[237]  F. Ferris,et al.  The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. , 2007, Archives of ophthalmology.

[238]  Judith Alexander,et al.  Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial. , 2009, Archives of ophthalmology.

[239]  N. J. Gibson,et al.  Lipid headgroup and acyl chain composition modulate the MI-MII equilibrium of rhodopsin in recombinant membranes. , 1993, Biochemistry.

[240]  S. Fisher,et al.  Case–control genetic association study of fibulin‐6 (FBLN6 or HMCN1) variants in age‐related macular degeneration (AMD) , 2007, Human mutation.

[241]  Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. , 2004, American journal of human genetics.

[242]  W. Renner,et al.  Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population. , 2007, Molecular vision.

[243]  R. Klein,et al.  The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. , 1993, Ophthalmology.

[244]  Robert B Wallace,et al.  Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. , 2006, Archives of ophthalmology.

[245]  S. Bonovas,et al.  The controversy over the association between statins use and progression of age-related macular degeneration: a mini review , 2010, Clinical ophthalmology.

[246]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[247]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.